Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

31.62
-0.4700-1.46%
Post-market: 31.620.00000.00%19:51 EDT
Volume:1.71M
Turnover:54.73M
Market Cap:3.97B
PE:-22.10
High:33.00
Open:32.09
Low:31.37
Close:32.09
52wk High:41.14
52wk Low:10.83
Shares:125.46M
Float Shares:109.51M
Volume Ratio:1.28
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4309
EPS(LYR):-1.5305
ROE:-74.73%
ROA:-44.13%
PB:16.59
PE(LYR):-20.66

Loading ...

Goldman Sachs Eyes $120 Oil Spike if Middle East Shipping Risks Continue

TIPRANKS
·
Jul 21

Hengyi Petrochemical Notes Product Prices Follow Crude Oil, But Profits Depend on Spreads

Deep News
·
Jul 20

Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock

Simply Wall St.
·
Jul 15

Amylyx Chief Legal Officer Gina Mazzariello Sells USD 539,362 of Common Stock

Reuters
·
Jul 14

Kodiak Gas Services, Baker Hughes Announce Multi-Year Gas Turbine Order Agreement to Support U.S. Data Center Growth

GlobeNewswire
·
Jul 08

Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN)

TIPRANKS
·
Jul 02

Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?

Simply Wall St.
·
Jun 27

Amylyx Pharmaceuticals is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 25

Amylyx reports clean safety in lowest-dose cohort of Phase 1 LUMINA trial of ALS drug AMX0114

Reuters
·
Jun 23

Amylyx Pharmaceuticals to Present Data From First-in-Human, Dose-Ranging Phase 1 Lumina Trial of Amx0114 in ALS at Encals 2026

THOMSON REUTERS
·
Jun 23

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jun 18

Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)

TIPRANKS
·
Jun 16

Amylyx to present avexitide Phase 3 LUCIDITY trial design poster at ENDO 2026

Reuters
·
Jun 08

Amylyx Pharmaceuticals shareholders elect Milne, Fonteyne as Class II directors

Reuters
·
Jun 05

HELIOS Wolfram Data And Patient Insights Could Be A Game Changer For Amylyx Pharmaceuticals (AMLX)

Simply Wall St.
·
May 29

Amylyx director Karen Firestone acquires $51,338 of common shares

Reuters
·
May 27

Do HELIOS Data Shift Amylyx (AMLX) From ALS Setback To Broader Rare-Disease Strategy Reboot?

Simply Wall St.
·
May 22

Amylyx announces publication of Phase 2 open-label HELIOS trial data

TIPRANKS
·
May 16

Amylyx posts Phase 2 HELIOS data showing AMX0035 benefits in Wolfram syndrome

Reuters
·
May 16

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label Helios Trial Data for Amx0035 in the Journal of Clinical Investigation

THOMSON REUTERS
·
May 16